HKSE - Delayed Quote HKD
Pharmaron Beijing Co., Ltd. (3759.HK)
13.980
+0.460
+(3.40%)
At close: 9:18:56 AM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
12,703,847.707
12,275,774.875
11,537,996.315
10,266,288.180
7,443,769.724
Cost of Revenue
8,329,952.661
8,072,643.718
7,413,512.033
6,497,890.212
4,764,854.017
Gross Profit
4,373,895.046
4,203,131.157
4,124,484.282
3,768,397.968
2,678,915.707
Operating Expense
2,376,874.174
2,338,755.546
2,291,155.236
2,017,812.172
1,154,058.061
Operating Income
1,997,020.871
1,864,375.610
1,833,329.046
1,750,585.796
1,524,857.646
Net Non Operating Interest Income Expense
-157,442.071
-174,302.356
-152,258.214
-134,633.824
-20,053.651
Pretax Income
2,186,231.144
2,091,263.494
1,837,886.586
1,666,391.305
1,910,995.517
Tax Provision
408,337.256
377,104.338
256,105.914
314,254.385
290,918.933
Net Income Common Stockholders
1,868,368.166
1,793,350.815
1,601,096.033
1,374,604.224
1,661,028.568
Basic EPS
1.06
1.01
0.90
0.78
0.93
Diluted EPS
1.05
1.01
0.90
0.77
0.91
Basic Average Shares
1,766,488.291
1,769,812.311
1,772,496.439
1,773,682.870
1,781,200.208
Diluted Average Shares
1,770,066.973
1,773,312.385
1,775,247.847
1,776,203.934
1,819,839.932
Total Operating Income as Reported
2,199,922.373
2,104,464.373
1,847,891.874
1,689,891.721
1,914,337.303
Rent Expense Supplemental
--
--
--
--
136,478.106
Total Expenses
10,706,826.836
10,411,399.265
9,704,667.269
8,515,702.384
5,918,912.079
Net Income from Continuing & Discontinued Operation
1,868,368.166
1,793,350.815
1,601,096.033
1,374,604.224
1,661,028.568
Normalized Income
1,991,935.384
1,923,762.783
1,623,627.362
1,340,198.507
1,571,921.876
Interest Income
56,029.055
73,631.412
33,542.987
35,213.061
64,406.935
Interest Expense
217,025.712
243,717.747
182,191.955
167,311.560
83,073.480
Net Interest Income
-157,442.071
-174,302.356
-152,258.214
-134,633.824
-20,053.651
EBIT
2,403,256.856
2,334,981.241
2,020,078.541
1,833,702.865
1,994,068.997
EBITDA
2,403,256.856
3,383,648.279
2,947,249.159
2,529,882.703
2,491,989.430
Reconciled Cost of Revenue
8,329,952.661
8,072,643.718
7,413,512.033
6,497,890.212
4,764,854.017
Reconciled Depreciation
--
1,048,667.039
927,170.618
696,179.837
497,920.433
Net Income from Continuing Operation Net Minority Interest
1,868,368.166
1,793,350.815
1,601,096.033
1,374,604.224
1,661,028.568
Total Unusual Items Excluding Goodwill
-151,947.482
-159,101.790
-26,179.373
42,402.058
105,107.678
Total Unusual Items
-151,947.482
-159,101.790
-26,179.373
42,402.058
105,107.678
Normalized EBITDA
2,555,204.338
3,542,750.069
2,973,428.533
2,487,480.644
2,386,881.752
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-28,380.264
-28,689.821
-3,648.045
7,996.341
16,000.987
12/31/2021 - 11/28/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade